Due to the significantly improved outcome and quality of life of patients with different tumor
entities after cytoreductive surgery (CRS) and HIPEC, there is an increasing number of …

Although cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy
(HIPEC) have not been shown to be effective by themselves, as a combined treatment they …

Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal
chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy …

Background Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mut BRAF)
or KRAS mutation (mut KRAS) have an inferior prognosis after liver or lung surgery, whereas …

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive
surgery has been extensively studied in patients with peritoneal carcinomatosis, and it holds …

Background and Objectives Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) can offer long‐term survival to patients with resectable peritoneal …

Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
achieve good results in selected patients with peritoneal carcinomatosis. High intra …

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen
or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision …

Overall outcomes for women with epithelial ovarian cancer (EOC) remain relatively poor,
and superior methods of treatment are needed. EOC is a peritoneal surface malignancy that …

Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is
increasingly used in the treatment of peritoneal malignancies. The administration of HIPEC …